A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT-1 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs LCB10-0200 (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Geom Therapeutics
- 22 May 2019 Status changed from recruiting to discontinued.
- 15 Feb 2019 Status changed from not yet recruiting to recruiting.
- 11 Feb 2019 Recruitment completion is expected on 30 Jul 2019 and First patient enrollment is expected on 6 Mar 2019, according to Australian New Zealand Clinical Trials Registry record.